Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel: +47 21 07 81 60
E-mail:

Copyright/Disclaimer

List of DDDs for 3 years revision

The DDDs, which will be reviewed at the March 2019 meeting (3 year revision) are listed below. See also Guidelines: Part III; D Principles for reviewing and changing DDD and Part V; D Requests for changes to DDDs. The deadline for applications for alterations and comments is 1 February 2019.

ATC code	ATC level name (INN/generic name)	DDD	Unit	Adm.route

A06AH03	naloxegol	25	mg	O
A16AB12	elosulfase alfa	20	mg	P
A16AB14	sebelipase alfa	5	mg	P
B01AC25	cangrelor	50	mg	P
B01AF03	edoxaban	60	mg	O
B01AX01	defibrotide	1.75	g	P
C10AX13	evolocumab	10	mg	P
C10AX14	alirocumab	5.4	mg	P
G03XB51	mifepristone, combinations	0.2	g ¹⁾	O
G04BX16	tiopronin	0.8	g	O
J01DI54	ceftolozone and beta-lactamase inhibitor	3	g ²⁾	P
J01XA04	dalbavancin	1.5	g ³⁾	P
J01XE03	furazidin	0.3	g	O
J01XX11	tedizolid	0.2	g	O,P
J02AC04	posaconazole	0.3	g	P
J02AC05	isavuconazole	0.2	g	O,P
J04AB05	rifapentine	0.11	g	O
L04AA32	apremilast	60	mg	O
L04AC10	secukinumab	10	mg	P
M01AE01	ibuprofen	1.2	g	P
M09AX03	ataluren	2.8	g	O
N03AX23	brivaracetam	0.1	g	O,P
N04BD03	safinamide	75	mg	O
N05AX14	iloperidone	18	mg	O
N05BA24	bentazepam	75	mg	O
N06BX13	idebenone	0.9	g	O
R03DA11	doxofylline	0.8	g	O,P
R03DX09	mepolizumab	3.6	mg	P
V03AE08	ferric citrate	6	g	O

1) Refers to mifepristone
2) Refers to ceftolozane
3) Course dose

Last updated: 2019-02-11